International Biotechnology Trust Stock Total Asset
| IBT Stock | 704.00 4.00 0.57% |
International Biotechnology Trust fundamentals help investors to digest information that contributes to International Biotechnology's financial success or failures. It also enables traders to predict the movement of International Stock. The fundamental analysis module provides a way to measure International Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to International Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 308.2 M | 204.7 M |
International | Total Asset |
International Biotechnology Trust Company Total Asset Analysis
International Biotechnology's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current International Biotechnology Total Asset | 308.15 M |
Most of International Biotechnology's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, International Biotechnology Trust is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
International Total Assets
Total Assets |
|
Based on the latest financial disclosure, International Biotechnology Trust has a Total Asset of 308.15 M. This is 99.87% lower than that of the Capital Markets sector and 99.04% lower than that of the Financials industry. The total asset for all United Kingdom stocks is 98.95% higher than that of the company.
International Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses International Biotechnology's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of International Biotechnology could also be used in its relative valuation, which is a method of valuing International Biotechnology by comparing valuation metrics of similar companies.International Biotechnology is currently under evaluation in total asset category among its peers.
International Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, International Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to International Biotechnology's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
International Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0806 | ||||
| Profit Margin | 0.91 % | ||||
| Operating Margin | 1.00 % | ||||
| Current Valuation | 271.71 M | ||||
| Shares Outstanding | 36.28 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 44.43 % | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 6.70 X | ||||
| Revenue | 40.14 M | ||||
| Gross Profit | (13.58 M) | ||||
| EBITDA | 39.55 M | ||||
| Net Income | 38.88 M | ||||
| Total Debt | 22.83 M | ||||
| Book Value Per Share | 7.66 X | ||||
| Cash Flow From Operations | 45.35 M | ||||
| Earnings Per Share | 1.02 X | ||||
| Beta | 0.21 | ||||
| Market Capitalization | 255.4 M | ||||
| Total Asset | 308.15 M | ||||
| Retained Earnings | (54.03 M) | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 308.15 M | ||||
| Last Dividend Paid | 0.28 |
About International Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze International Biotechnology Trust's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of International Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of International Biotechnology Trust based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in International Stock
International Biotechnology financial ratios help investors to determine whether International Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in International with respect to the benefits of owning International Biotechnology security.